Want to see BIOQ full AI Analyst Report?
Top Page
Bioqual
(OTC:BIOQ)
Select Model
Select Model
Rating:44Neutral
Price Target:
$33.00
▼(-2.94% Downside)
Action:Reiterated
Date:09/23/26
The score is driven primarily by weak financial performance—declining revenue, sharply worsening losses, deteriorating cash generation, and higher leverage—raising the company’s near-term risk profile. Technical indicators are neutral and do not offset the fundamentals, while valuation is constrained by a negative P/E and the absence of a dividend yield.
Positive Factors
Positive operating cash flow
The company is still generating cash from operations, which provides some internal funding for ongoing activities despite the recent deterioration. This is a meaningful buffer because positive operating cash flow can help support continuity while management works to address weaker earnings and revenue.
Negative Factors
Persistent revenue decline
Consistent revenue contraction signals weakening demand, reduced business scale, or both, and makes recovery more difficult because fixed costs are spread across a smaller sales base. Continued top-line pressure can also limit investment capacity and prolong the earnings deterioration.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive operating cash flow
The company is still generating cash from operations, which provides some internal funding for ongoing activities despite the recent deterioration. This is a meaningful buffer because positive operating cash flow can help support continuity while management works to address weaker earnings and revenue.
Read all positive factors
Bioqual (BIOQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$30.17M
Dividend Yield0.74%
Average Volume (3M)40.00
Price to Earnings (P/E)―
Beta (1Y)-0.19
Revenue Growth-18.25%
EPS Growth-297.70%
CountryUS
Employees278
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-4.66
Shares Outstanding893,838
10 Day Avg. Volume0
30 Day Avg. Volume40
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.90
Price to Sales (P/S)0.73
P/FCF Ratio-435.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bioqual Business Overview & Revenue Model
Company Description
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans nume...
Bioqual Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
41
Neutral
Cash Flow
36
Negative
| Breakdown | Aug 2025 | Aug 2024 | Aug 2023 | May 2023 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 39.95M | 48.87M | 58.59M | 62.66M | 66.15M |
| Gross Profit | 1.43M | -1.90M | 7.43M | 12.60M | 13.01M |
| EBITDA | -2.25M | 509.61K | 3.03M | 6.97M | 14.76M |
| Net Income | -4.17M | -1.05M | 483.48K | 835.55K | 5.26M |
Balance Sheet | |||||
| Total Assets | 68.44M | 57.12M | 56.59M | 61.32M | 63.34M |
| Cash, Cash Equivalents and Short-Term Investments | 16.01M | 17.85M | 15.59M | 7.28M | 2.18M |
| Total Debt | 32.71M | 16.54M | 3.59M | 18.61M | 18.72M |
| Total Liabilities | 36.04M | 20.96M | 18.94M | 23.70M | 25.67M |
| Stockholders Equity | 32.41M | 36.15M | 37.65M | 37.61M | 37.67M |
Cash Flow | |||||
| Free Cash Flow | -66.78K | 2.71M | 8.76M | 5.99M | -4.57M |
| Operating Cash Flow | 351.44K | 2.94M | 9.36M | 8.23M | 313.36K |
| Investing Cash Flow | -7.08M | -238.78K | -597.13K | -2.24M | -4.73M |
| Financing Cash Flow | 0.00 | -447.21K | -447.21K | -894.42K | -1.12M |
Bioqual Technical Analysis
Neutral
34.00
Price Trends
33.74
Positive
34.03
Negative
35.68
Negative
Market Momentum
<0.01
Negative
50.35
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOQ, the sentiment is Neutral. The current price of 34 is above the 20-day moving average (MA) of 33.71, above the 50-day MA of 33.74, and below the 200-day MA of 35.68, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.35 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIOQ.
Bioqual Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $42.21M | -36.45 | -8.49% | ― | 28.04% | 43.26% | |
61 Neutral | $307.46M | -9.60 | -788.19% | ― | 34.46% | 43.48% | |
52 Neutral | $20.37M | -0.45 | -78.78% | ― | 10.03% | 91.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $7.15M | -0.07 | 77.10% | ― | 86.32% | 21.31% | |
44 Neutral | $30.17M | -7.08 | -11.99% | 0.74% | -18.25% | -297.70% |
* Healthcare Sector Average
BIOQ
Bioqual
33.75
-6.25
-15.63%
VNRX
VolitionRX
0.26
-13.32
-98.11%
PRPO
Precipio
23.58
5.79
32.55%
BNGO
BioNano Genomics
1.73
0.02
1.17%
BDSX
Biodesix
29.14
21.59
285.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.